173 related articles for article (PubMed ID: 36719059)
1. PNPLA3 I148M and response to treatment for hepatic steatosis: A systematic review.
Boeckmans J; Gatzios A; Schattenberg JM; Koek GH; Rodrigues RM; Vanhaecke T
Liver Int; 2023 May; 43(5):975-988. PubMed ID: 36719059
[TBL] [Abstract][Full Text] [Related]
2. The rs2294918 E434K variant modulates patatin-like phospholipase domain-containing 3 expression and liver damage.
Donati B; Motta BM; Pingitore P; Meroni M; Pietrelli A; Alisi A; Petta S; Xing C; Dongiovanni P; del Menico B; Rametta R; Mancina RM; Badiali S; Fracanzani AL; Craxì A; Fargion S; Nobili V; Romeo S; Valenti L
Hepatology; 2016 Mar; 63(3):787-98. PubMed ID: 26605757
[TBL] [Abstract][Full Text] [Related]
3. Four-Week Omega-3 Supplementation in Carriers of the Prosteatotic PNPLA3 p.I148M Genetic Variant: An Open-Label Study.
Kuttner CS; Mancina R; Wagenpfeil G; Lammert F; Stokes CS
Lifestyle Genom; 2019; 12(1-6):10-17. PubMed ID: 31454802
[TBL] [Abstract][Full Text] [Related]
4. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
[TBL] [Abstract][Full Text] [Related]
5. Review article: the emerging role of genetics in precision medicine for patients with non-alcoholic steatohepatitis.
Carlsson B; Lindén D; Brolén G; Liljeblad M; Bjursell M; Romeo S; Loomba R
Aliment Pharmacol Ther; 2020 Jun; 51(12):1305-1320. PubMed ID: 32383295
[TBL] [Abstract][Full Text] [Related]
6. Patatin-like phospholipase domain-containing 3 (PNPLA3) I148M (rs738409) affects hepatic VLDL secretion in humans and in vitro.
Pirazzi C; Adiels M; Burza MA; Mancina RM; Levin M; Ståhlman M; Taskinen MR; Orho-Melander M; Perman J; Pujia A; Andersson L; Maglio C; Montalcini T; Wiklund O; Borén J; Romeo S
J Hepatol; 2012 Dec; 57(6):1276-82. PubMed ID: 22878467
[TBL] [Abstract][Full Text] [Related]
7. Patatin-like phospholipase domain containing-3 gene I148M polymorphism, steatosis, and liver damage in hereditary hemochromatosis.
Valenti L; Maggioni P; Piperno A; Rametta R; Pelucchi S; Mariani R; Dongiovanni P; Fracanzani AL; Fargion S
World J Gastroenterol; 2012 Jun; 18(22):2813-20. PubMed ID: 22719190
[TBL] [Abstract][Full Text] [Related]
8. Pnpla3 silencing with antisense oligonucleotides ameliorates nonalcoholic steatohepatitis and fibrosis in Pnpla3 I148M knock-in mice.
Lindén D; Ahnmark A; Pingitore P; Ciociola E; Ahlstedt I; Andréasson AC; Sasidharan K; Madeyski-Bengtson K; Zurek M; Mancina RM; Lindblom A; Bjursell M; Böttcher G; Ståhlman M; Bohlooly-Y M; Haynes WG; Carlsson B; Graham M; Lee R; Murray S; Valenti L; Bhanot S; Åkerblad P; Romeo S
Mol Metab; 2019 Apr; 22():49-61. PubMed ID: 30772256
[TBL] [Abstract][Full Text] [Related]
9. Human hepatocyte PNPLA3-148M exacerbates rapid non-alcoholic fatty liver disease development in chimeric mice.
Kabbani M; Michailidis E; Steensels S; Fulmer CG; Luna JM; Le Pen J; Tardelli M; Razooky B; Ricardo-Lax I; Zou C; Zeck B; Stenzel AF; Quirk C; Foquet L; Ashbrook AW; Schneider WM; Belkaya S; Lalazar G; Liang Y; Pittman M; Devisscher L; Suemizu H; Theise ND; Chiriboga L; Cohen DE; Copenhaver R; Grompe M; Meuleman P; Ersoy BA; Rice CM; de Jong YP
Cell Rep; 2022 Sep; 40(11):111321. PubMed ID: 36103835
[TBL] [Abstract][Full Text] [Related]
10. PNPLA3 I148M Variant Influences Circulating Retinol in Adults with Nonalcoholic Fatty Liver Disease or Obesity.
Mondul A; Mancina RM; Merlo A; Dongiovanni P; Rametta R; Montalcini T; Valenti L; Albanes D; Romeo S
J Nutr; 2015 Aug; 145(8):1687-91. PubMed ID: 26136587
[TBL] [Abstract][Full Text] [Related]
11. Long-term hypercaloric diet exacerbates metabolic liver disease in PNPLA3 I148M animals.
Su H; Haque M; Becker S; Edlund K; Duda J; Wang Q; Reißing J; Marschall HU; Candels LS; Mohamed M; Sjöland W; Liao L; Drexler SA; Strowig T; Rahnenführer J; Hengstler JG; Hatting M; Trautwein C
Liver Int; 2023 Aug; 43(8):1699-1713. PubMed ID: 37073116
[TBL] [Abstract][Full Text] [Related]
12. Patatin-like phospholipase domain-containing 3 I148M affects liver steatosis in patients with chronic hepatitis B.
Viganò M; Valenti L; Lampertico P; Facchetti F; Motta BM; D'Ambrosio R; Romagnoli S; Dongiovanni P; Donati B; Fargion S; Colombo M
Hepatology; 2013 Oct; 58(4):1245-52. PubMed ID: 23564580
[TBL] [Abstract][Full Text] [Related]
13. PNPLA3 I148M is involved in the variability in anti-NAFLD response to exenatide.
Chen Y; Yan X; Xu X; Yuan S; Xu F; Liang H
Endocrine; 2020 Dec; 70(3):517-525. PubMed ID: 32862405
[TBL] [Abstract][Full Text] [Related]
14. Patatin-Like Phospholipase Domain-Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population.
Unalp-Arida A; Ruhl CE
Hepatology; 2020 Mar; 71(3):820-834. PubMed ID: 31705824
[TBL] [Abstract][Full Text] [Related]
15. Patatin-like phospholipase domain-containing 3 gene (PNPLA3) polymorphic (rs738409) single nucleotide polymorphisms and susceptibility to nonalcoholic fatty liver disease: A meta-analysis of twenty studies.
Zhao Y; Zhao W; Ma J; Toshiyoshi M; Zhao Y
Medicine (Baltimore); 2023 Mar; 102(10):e33110. PubMed ID: 36897668
[TBL] [Abstract][Full Text] [Related]
16. PPARGC1A rs8192678 G>A polymorphism affects the severity of hepatic histological features and nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease.
Zhang RN; Shen F; Pan Q; Cao HX; Chen GY; Fan JG
World J Gastroenterol; 2021 Jul; 27(25):3863-3876. PubMed ID: 34321850
[TBL] [Abstract][Full Text] [Related]
17. Treating liver fat and serum triglyceride levels in NAFLD, effects of PNPLA3 and TM6SF2 genotypes: Results from the WELCOME trial.
Scorletti E; West AL; Bhatia L; Hoile SP; McCormick KG; Burdge GC; Lillycrop KA; Clough GF; Calder PC; Byrne CD
J Hepatol; 2015 Dec; 63(6):1476-83. PubMed ID: 26272871
[TBL] [Abstract][Full Text] [Related]
18. The I148M PNPLA3 polymorphism influences serum adiponectin in patients with fatty liver and healthy controls.
Valenti L; Rametta R; Ruscica M; Dongiovanni P; Steffani L; Motta BM; Canavesi E; Fracanzani AL; Mozzi E; Roviaro G; Magni P; Fargion S
BMC Gastroenterol; 2012 Aug; 12():111. PubMed ID: 22898488
[TBL] [Abstract][Full Text] [Related]
19. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
[TBL] [Abstract][Full Text] [Related]
20. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents.
Mosca A; Fintini D; Scorletti E; Cappa M; Paone L; Zicari AM; Nobili V; Byrne CD
Liver Int; 2018 Dec; 38(12):2301-2308. PubMed ID: 30176114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
